Categories: News

Elliott Management Statement on Toyota Industries Corporation

Toyota Fudosan’s tender offer drastically undervalues the Company

- Advertisement -

Elliott does not intend to tender its shares into the Revised TOB at the current terms and strongly encourages other shareholders not to tender

- Advertisement -

LONDON, Feb. 2, 2026 /PRNewswire/ — Elliott Investment Management L.P. and Elliott Advisors (UK) Limited (“Elliott”), which advise funds that together have a significant investment in Toyota Industries Corporation (“Toyota Industries” or the “Company”) and are the Company’s largest independent shareholder, today issued the following statement:

- Advertisement -

Elliott notes the non-binding statement issued today by an affiliate of Toyota Fudosan Co., Ltd. (“Toyota Fudosan”). Elliott maintains its position that the revised tender offer by Toyota Fudosan at ¥18,800 per share (the “Revised TOB”) very significantly undervalues Toyota Industries, as Elliott demonstrates in its public materials. Elliott continues to strongly disagree with Toyota Fudosan’s assertion that the Revised TOB price “reflects the intrinsic value of the Target Company“.

- Advertisement -

Elliott does not intend to tender its shares into the Revised TOB at the current terms and strongly encourages other shareholders not to tender.

- Advertisement -

Elliott’s previously released public materials can be found at https://elliottletters.com

- Advertisement -

About Elliott

- Advertisement -

Elliott Investment Management L.P. (together with its affiliates, “Elliott”) manages approximately $76.1 billion of assets as of June 30, 2025. Founded in 1977, it is one of the oldest funds under continuous management. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, high net worth individuals and families, and employees of the firm. Elliott Advisors (UK) Limited is an affiliate of Elliott Investment Management L.P.

- Advertisement -

Investor Contacts:

- Advertisement -

Okapi Partners LLC
New York: Pat McHugh
T:+1 212 297 0720
Toll Free: (877) 629-6357
London: Christian Jacques
T: +44 20 3031 6613
TICO@okapipartners.com

- Advertisement -

Media Contacts:

- Advertisement -

London
Stijn van de Grampel
Elliott Advisors (UK) Limited
T: +44 20 3009 1061
svdgrampel@elliottadvisors.co.uk

- Advertisement -

New York
Stephen Spruiell
Elliott Investment Management L.P.
T: +1 (212) 478-2017
sspruiell@elliottmgmt.com

- Advertisement -

Tokyo
Brett Wallbutton
Ashton Consulting
T: +81 (0) 3 5425-7220
b.wallbutton@ashton.jp

- Advertisement -

Logo – https://mma.prnewswire.com/media/2705826/5748241/Elliott_WhiteText_Green_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/elliott-management-statement-on-toyota-industries-corporation-302676899.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

3 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

3 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

3 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

3 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

3 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

3 hours ago